|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/167 | (2006.01) |
| A61K 38/08 | (2006.01) | ||
| A61K 31/165 | (2006.01) | ||
| A61K 38/04 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 38/55 | (2006.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 38/06 | (2006.01) | ||
| A61K 31/198 | (2006.01) |
| (11) | Number of the document | 2796134 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14171395.8 |
| Date of filing the European patent application | 2009-10-21 | |
| (97) | Date of publication of the European application | 2014-10-29 |
| (45) | Date of publication and mention of the grant of the patent | 2016-12-07 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 196945 P | 2008-10-21 | US |
| (72) |
Kirk, Christopher J., US
Demo, Susan D., US
Bennett, Mark K., US
|
| (73) |
Onyx Therapeutics, Inc.,
One Amgen Center Drive, Thousand Oaks, CA 91320,
US
|
| (54) | Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma |
| Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma |